Loading...
SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Nathan, P Needham, A Corrie, PG Danson, S Evans, J Ochsenreither, S Kumar, S Goodman, A Larkin, JMG Karydis, I
Nathan, P
Needham, A
Corrie, PG
Danson, S
Evans, J
Ochsenreither, S
Kumar, S
Goodman, A
Larkin, JMG
Karydis, I
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Nathan P, Needham A, Corrie PG, Danson S, Evans J, Ochsenreither S, et al. LBA73SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Annals of Oncology. 2019;30(Supplement_5).